FOXO1 and cancer: Arzanol’s reduction in both SIRT1 protein expression and enzymatic activity, with concurrent downregulation of FOXO1 signaling, provides a plausible link between SIRT1 inhibition and the selective cytotoxicity observed by Rosa et al. (2017) [4], though direct validation in cancer cell models remains necessary to confirm this mechanistic connection.